Table 2

Survival in NSCLC based on clinical and molecular parameters

Parametern5-yr survival probabilityRRaMedian survival (mo)95% CIPb
UICC stage
 I410.71 ± 0.071.00n.r.c<0.001
 II160.44 ± 0.122.1133.97 ± 5.7022.80; 45.14
 IIIa260.12 ± 0.064.8119.00 ± 5.148.92; 29.08
pT
 pT1160.69 ± 0.121.00n.r.0.016
 pT2540.46 ± 0.072.1646.77 ± 18.5110.49; 83.05
 pT3130.23 ± 0.123.5626.67 ± 6.0914.73; 38.61
pN
 pN0460.70 ± 0.071.00n.r.<0.001
 pN1220.32 ± 0.102.5133.71 ± 6.8620.22; 47.12
 pN2150.00 ± 0.006.5916.70 ± 4.018.84; 24.56
HER2-neu
 Low540.59 ± 0.071.00n.r.0.004
 High290.24 ± 0.082.2731.10 ± 4.6621.96; 40.24
EGFR
 Low550.53 ± 0.071.00n.r.0.176
 High280.36 ± 0.091.5032.37 ± 12.228.43; 56.31
Double marker (HER2/EGFR)
 Low/Low400.63 ± 0.081.00n.r.0.003
 Low/High140.50 ± 0.131.3945.47
 High/Low150.27 ± 0.112.3431.10 ± 8.3314.77; 47.73
 High/High140.21 ± 0.112.6522.03 ± 10.072.30; 41.76
  • a RR, relative risk. RR can be thought of as the average increased risk of dying at any point in time for patients in the second group compared with those in the first group.

  • b Based on median survival (log-rank test).

  • c n.r., not reached, cannot be calculated.